Novartis AG has proposed the acquisition of Avidity Biosciences to enhance its innovative drug portfolio and strengthen its capabilities in RNA-targeting therapeutics, particularly in neurology, aligning with the company's strategic focus on expanding its pipeline in the evolving biopharmaceutical landscape.

Information on the target

Novartis AG, a global healthcare company based in Basel, Switzerland, specializes in innovative pharmaceuticals. The company reported a net revenue growth of 8% for the fiscal year 2025, driven by strong performances from key brands such as Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx. The operational core earnings improved by 14%, reflecting the company's commitment to enhancing its product offerings and market presence.

In the fourth quarter of 2025, Novartis faced a slight decline in net revenue due to generic competition and revenue adjustments in the U.S. However, the operational core earnings continued to show resilience, indicating the strength of its priority brands. The company has also made significant strides in its pipeline, with several promising drug candidates nearing approval.

Industry overview in the target’s specific country

Switzerland is home to a robust pharmaceutical industry, characterized by a strong emphasis on research and development. The country is recognized as a global leader in the production of innovative medicines, with major companies like Novartis and Roche d